Company intelligence / Profile preview

ELSE

San Diego, California, United Stateselsenutrition.com ↗

Ownership: Private
Development stage: Commercial

Overview

Elsie's proprietary platform enables comprehensive exploration of oligonucleotide chemical space to optimize efficacy, safety, and delivery. The company did not have publicly disclosed clinical results before its acquisition by GSK. Its technologies are now being used within GSK’s pipeline development for next-generation RNA therapeutics targeting previously undruggable conditions.

Therapeutic areas: GastroenterologyRare DiseasesNeurologyInfectious Diseases
Modalities: Antisense oligonucleotideRNA therapyOligonucleotide (general)Small molecule (for P(V) chemistry platform applications)
Industry: Biotech

Partnerships

Research collaboration and subsequent integration with GSK [initiated July 2023–acquisition completed June 2024].

Beyond the preview

Go deeper on ELSE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELSE.

Explore the full profile